Cardiovascular Disease Risk in Women With Endometriosis

StatusCompleted
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 7 more changesShow less
    • Results posted: Oct 16, 2026
    • Trial completed
    • Final enrollment: 21 participants (planned 40)
    • Primary completion date changed from estimate of Dec 1, 2025 to May 27, 2025
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints expanded, about 12 words
    • Site details revised
  2. Enrollment target: 17 to 40v12
  3. Study site revisedv11
  4. Enrollment target: 24 to 17
    • Primary completion date: Aug 30, 2025 to Dec 1, 2025
    • Study completion date: Aug 30, 2025 to Dec 31, 2026
    v10
  5. Re-verified, no change to tracked fieldsv9
Show 7 earlier versionsHide 7 earlier versions
  1. Collaborators expanded, about 7 wordsv8
  2. Enrollment target: 72 to 24v7
  3. Phase: Not applicable to Early Phase 1
    • Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 30, 2022 to Jul 1, 2022
    v6
  4. Start date: Nov 30, 2021 to May 30, 2022v5
  5. Start date: Jun 30, 2021 to Nov 30, 2021
    • Primary endpoints: 3 to 2
    • Interventions: Ganirelix Acetate (Drug) to Elagolix (Drug)
    v4
  6. Primary and study completion dates: Aug 30, 2022 to Aug 30, 2025
    • Start date: Sep 30, 2020 to Jun 30, 2021
    v3
  7. Start date: Jan 31, 2019 to Sep 30, 2020v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yale University
490 trials monitored
See 31 trials at risk
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Trial Details
NCT Number NCT03746535
Lead Sponsor Yale University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Endometriosis
Related terms Endometriosis
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov